Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2000
Key Context: The Company announced the planned divestiture of its Clairol and Zimmer businesses, reclassifying them as discontinued operations effective Q3 2000. The Company reduced its reporting segments from four to one, focusing on the medicines business.
Key Financial Metrics
| Metric (in millions) | Q3 2000 | Q3 1999 | 9M 2000 | 9M 1999 |
|---|---|---|---|---|
| Net Sales | $4,563 | $4,190 | $13,432 | $12,288 |
| Net Earnings (Continuing Ops) | $893 | $988 | $3,027 | $2,829 |
| Net Earnings (Total) | $1,236 | $1,097 | $3,548 | $3,115 |
| Diluted EPS (Total) | $0.62 | $0.54 | $1.77 | $1.54 |
| Operating Cash Flow (9M) | $2,832 | $2,674 | ||
| Cash & Equivalents (End Period) | $2,760 | |||
| Short-Term Borrowings | $173 | |||
| Long-Term Debt | $1,323 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% in Q3 and 9% for the nine months ended Sept 30, 2000, compared to the prior year. Growth was driven by volume (8%) and price (3%), partially offset by foreign exchange (2%).
- Restructuring Charges: The Company recorded a pre-tax restructuring charge of $386 million in Q3 and $508 million for the nine months, primarily for workforce reductions and facility closures. Excluding these charges, earnings from continuing operations increased 14% in Q3 and 14% for the nine months.
- Discontinued Operations: Significant gains were recorded from the sale of Matrix Essentials Inc. (Clairol affiliate), resulting in a $402 million pre-tax gain in Q3. Clairol and Zimmer results are now reported as discontinued operations.
- Product Performance: Key pharmaceutical sales grew significantly: PLAVIX (+58% Q3), AVAPRO (+61% Q3), GLUCOPHAGE (+25% Q3), and TAXOL (+11% Q3).
- Debt Reduction: Short-term borrowings decreased to $173 million from $432 million at year-end 1999. Long-term debt remained relatively stable at $1.323 billion.
Guidance, Outlook, and Risks
- Restructuring Completion: Management expects to substantially complete restructuring activities related to Q3 charges by mid-2001 and earlier charges by the end of 2000.
- Divestitures: The Company expects to divest Clairol and Zimmer businesses in 2001.
- Regulatory Approvals: Recent approvals include GLUCOVANCE, VANIQA, and VIDEX EC. The Company is seeking approval for UFT (colorectal cancer therapy).
- Legal Proceedings:
- Breast Implant Litigation: Approximately 950 remaining opt-out plaintiffs; Company believes reserves are sufficient.
- TAXOL Litigation: Appeal pending regarding patent validity after a District Court ruling invalidated most claims. Generic competitors received FDA approval in September 2000.
- VANLEV Litigation: Class action lawsuits filed alleging false statements regarding product safety and availability.
- Accounting Changes: Adoption of SFAS 133 (Derivatives) effective Jan 1, 2001; not expected to have a material effect.
Investor Verification Checklist
- Verify the impact of the $508 million restructuring charge on future operating costs and cash flow.
- Monitor the outcome of the TAXOL patent appeal and the potential erosion of market share due to generic entry.
- Assess the timeline and financial terms of the planned Clairol and Zimmer divestitures in 2001.
- Review the status of the VANLEV litigation and potential liability exposure.
- Confirm the sustainability of double-digit growth rates for key products like PLAVIX and AVAPRO.